Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | ADH1C | P00326 | 1/20 | 0.43 |
| ▸ | ADH1A | P07327 | 1/20 | 0.43 |
| ▸ | ADH4 | P08319 | 1/20 | 0.43 |
| ▸ | ADH7 | P40394 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451574 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL18985093 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL4699570 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL2670965 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL1831666 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL14732171 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL7263751 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL276282 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL7259802 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B | |
| SCHEMBL3307877 | 1.00 | FDPS (0.46) | FDPSMAPTOPRM1GPR84ADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640536-B2 | Polymyxins, compositions, methods of making and methods of use | XELLIA PHARMACEUTICALS APS (DK) | 2020-05-05 | — | — | US | claimed |
| EP-2943503-B1 | POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | XELLIA PHARMACEUTICALS APS (DK) | 2017-08-23 | — | — | EP | claimed |
| US-20160002296-A1 | POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | XELLIA PHARMACEUTICALS APS (DK) | 2016-01-07 | — | — | US | claimed |
| EP-2943503-A1 | POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | Xellia Pharmaceuticals ApS (DK) | 2015-11-18 | — | — | EP | claimed |
| CN-104364239-A | New diazaspirocycloalkane and azaspirocycloalkane | HOFFMANN LA ROCHE | 2015-02-18 | — | — | CN | claimed |
| WO-2014108469-A1 | POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | XELLIA PHARMACEUTICALS APS (DK) | 2014-07-17 | — | — | WO | claimed |
| EP-0337731-B1 | Peptide antibiotics | LILLY CO ELI (US) | 1996-01-31 | — | — | EP | claimed |
| US-5352689-A | Rhizoxin derivatives and their use as anti-tumor agents | SANKYO COMPANY, LIMITED (JP) | 1994-10-04 | — | — | US | claimed |
| EP-0337731-A2 | Peptide antibiotics | ELI LILLY AND COMPANY (US) | 1989-10-18 | — | — | EP | claimed |
| WO-2024146502-A1 | WEE1 DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2024-07-11 | — | — | WO | disclosed |
| CN-111848778-B | Teriparatide analogues | 上海医药工业研究院 | 2024-03-19 | — | — | CN | disclosed |
| CN-111358713-B | copolymer | 宝丽化学工业有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-111481469-B | copolymer | 宝丽化学工业有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-111329787-B | Copolymer | 宝丽化学工业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-0350315-B1 | RHIZOXIN DERIVATES AND THEIR USE AS ANTI-TUMOR AGENTS | SANKYO COMPANY LIMITED (JP) | 1993-06-16 | — | — | EP | disclosed |
| US-5137653-A | Alkanoyl ester compounds and their intermediates and method of producing the same | NIPPON MINING CO., LTD. (JP) | 1992-08-11 | — | — | US | disclosed |
| EP-0311692-B1 | NOVEL ALKANOYL ESTER COMPOUNDS, INTERMEDIATES THEREFOR, AND PROCESSES FOR THEIR PREPARATION | NIPPON MINING COMPANY LIMITED (JP) | 1992-07-08 | — | — | EP | disclosed |
| EP-0350315-A1 | Rhizoxin derivates and their use as anti-tumor agents | SANKYO COMPANY LIMITED (JP) | 1990-01-10 | — | — | EP | disclosed |
| EP-0337731-A2 | Peptide antibiotics | ELI LILLY AND COMPANY (US) | 1989-10-18 | — | — | EP | disclosed |
| EP-0311692-A1 | NOVEL ALKANOYL ESTER COMPOUNDS, INTERMEDIATES THEREFOR, AND PROCESSES FOR THEIR PREPARATION | NIPPON MINING COMPANY LIMITED (JP) | 1989-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002296-A1 | POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | C5, SGMS1, SGMS2 | FDPS 4338/4885MAPT 4868/4885OPRM1 153/4885 |
| US-10640536-B2 | Polymyxins, compositions, methods of making and methods of use | C5, HRH3, SGMS1 | FDPS 4369/4885MAPT 4871/4885OPRM1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.